| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-569
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 |
| filingDate |
2018-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2020-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2020537689-A |
| titleOfInvention |
Leukocytosis preparations containing A-nor-5α-androstane compounds and their use |
| abstract |
Leukocytosis preparations containing A-nor-5α-androstane compounds and their use. The A-nor-5α androstan compound can prevent, alleviate and ameliorate the decrease in white blood cell count due to chemotherapy or radiotherapy, and is used for (a) improvement of white blood cell count or (b) prevention or treatment of leukopenia. It is useful in the manufacture of formulations or compositions used. |
| priorityDate |
2017-10-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |